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ABSTRACT
Background: Nesfatin-1 is a newly identified satiety peptide that has regulatory effects on 
food intake and glucose metabolism, and is located in the hypothalamic nuclei, including 
the supraoptic nucleus (SON). In this study, we have investigated the hypothesis that 
nesfatin-1 neurons are activated by refeeding and intraperitoneal (ip) glucose injection and 
that the glutamatergic system has regulatory influences on nesfatin-1 neurons in the SON. 
Materials and methods: The first set of experiments analyzed activation of nesfatin-1 
neurons after refeeding as a physiological stimulus and the effectiveness of the 
glutamatergic system on this physiological stimulation. The subjects were randomly 
divided into three groups: fasting group, refeeding group and antagonist 
(CNQX+refeeding) group.  The second set of experiments analyzed activation of nesfatin-
1 neurons by glucose injection as a metabolic stimulus and the effectiveness of the 
glutamatergic system on this metabolic stimulation. The subjects were randomly divided 
into three groups: saline group, glucose group and antagonist (CNQX+glucose) group. 
Results: Refeeding significantly increased the number of activated nesfatin-1 neurons by 
1
approximately 66%, and intraperitoneal glucose injection activated these neurons by about 
55%, compared to the fasting and saline controls. The injections of glutamate antagonist 
(CNQX) greatly decreased the number of activated nesfatin-1 neurons.
Conclusions: This study suggested that nesfatin-1 neurons were activated by peripheral 
and/or metabolic signals and that this effect was mediated through the glutamatergic 
system.
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INTRODUCTION
Nesfatin-1 is an 82 amino acid peptide that has modulating effects in regulating 
food intake, body weight and gluconeogenesis (11, 41). NUCB2/Nesfatin-1 is widely 
expressed in peripheral tissues and the central nervous system (51). Nesfatin-1 is expressed
in the hypothalamic nuclei which are involved with the regulation of food intake including 
the paraventricular nucleus (PVN), arcuate nucleus (ARC), supraoptic nucleus (SON), 
lateral hypothalamic area (LHA), zona incerta, and the solitary tract (11, 23, 41, 43, 44). 
NUCB2/Nesfatin-1 has also shown to be expressed in the periphery such as the gastric 
mucosa, adipose tissue, ovaries, testes, uterus, epididymis, cardiomyocytes and pancreatic 
beta cells (41). Surprisingly, NUCB2/Nesfatin-1 immunoreactivity was found to be 10 
times higher in the gastric mucosa than in the brain (15). The inhibitory effects on food 
intake of nesfatin-1 have been studied and it has also been shown to influence the 
regulation of cardiac functions, lipid metabolism, glucose homeostasis and reproductive 
functions (5). It has been shown that intracerebroventricular injection of nesfatin-1 into the 
3rd and 4th ventricles reduces food intake in mice and rats (29, 35, 44, 49).
Immunohistochemically, the expression of transcription factors such as c-Fos, 
phosphorylated CREB or phosphorylated STATs (phosphorylated signal transducers and 
transcription activators) are used as markers for determining neuronal activity changes (1, 
4, 20, 52). Nesfatin-1 injection to the third ventricle has been shown to cause c-Fos 
expression, especially in the PVN and NTS (11, 29). The expression of c-Fos in these 
nuclei shows the anorectic signaling mechanism of nesfatin-1 (11).
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Glucose sensitive neurons include glucose homeostasis and glucoprivic feeding. 
Recently, these neurons have received more attention due to their regulatory effects on 
appetite (51). Nesfatin-1 inhibits food intake by increasing the number of the glucose 
sensitive neurons in the hypothalamus (dorsal vagal complex) (51). Nesfatin-1 participates 
in blood glucose regulation. Subcutaneous injection of nesfatin-1 reduces the glucose 
levels in the blood during the oral glucose tolerance test (OGTT). However, 
intracerebroventricular injection of nesfatin-1 does not reduce glucose levels in the blood 
(28). This finding suggests that the glycemic effect of nesfatin-1 may be peripheral. Co-
injection of insulin and nesfatin-1 increased the phosphorylation of AKT kinase in liver, 
skeletal muscle and adipose tissue. As a result, GluT4 expression increased to increase 
glucose uptake (15).
Glutamate is the major excitatory amino acid neurotransmitter in the mammalian 
central nervous system (7, 8). Glutamate plays an important role in the regulation of the 
neuroendocrine systems and the hypothalamus-pituitary-endocrine system axis by acting 
on many neuroendocrine and peptidergic neurons localized in the hypothalamus (7, 8, 40). 
Glutamate-mediated neurotransmission occurs via metabotropic and ionotropic glutamate 
receptors (22). Ionotropic glutamate receptors are classified according to their agonists: N-
methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) and 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine (kainate) receptors (22,
27, 45). NMDA receptors are composed of subunits named GluN1, GluN2A-D and 
GluN3A-B (9, 24). These receptors have a critical function in excitatory synaptic 
transmission, plasticity and neurotoxicity (10, 30, 36-38).
Despite the many publications describing the mechanisms of action of nesfatin-1, 
there are no data about the peripheral and central control systems which play a role in the 
regulation of nesfatin-1 neuron activation. In this study, we analyzed the effects of 
glutamatergic receptor antagonist (CNQX) on the activation of Nesfatin-1 neurons 




All animal experiments were carried out in accordance with the National Institute 
of Health Guide for the Care and Use of Laboratory Animals and approved by the 
Experimental Ethics Committee of Bursa Uludag University (Date: 01.03.2016, No: 
HDP(T)-2016/25). 60-day-old male Sprague-Dawley rats (200-250 g) (n=30), obtained 
from the Bursa Uludag University Laboratory Animal Breeding, Usage and Research 
Center, were used in this study. Animals were kept in a light- and temperature-controlled 
facility (12:12 h light-dark cycle with lights off at 7:00 am and at 21°C) with water freely 
available.
Experimental groups
Experiment 1: Suppressive effect of glutamate receptor antagonist (CNQX) on nesfatin-
1 neuronal activation induced by refeeding
The animals were divided into three groups (n= 5 per group). After a 48-hour 
fasting period, the refeeding group was allowed to eat ad libitum for 2 hours, while the 
fasting group was unfed and the antagonist group was injected intraperitoneally with non-
NMDA glutamate antagonist (CNQX) (2 mg/kg CNQX in 300 µl distilled water, DW) 15 
minutes before the 2-h refeeding period. After the 48-hour fasting, refeeding was started at 
9:00 am at the beginning of the dark period of the dark-light cycle and the animals were 
allowed to feed for 2 hours. Also, the CNQX injections were performed at 9:00 am. 
Experiment 2: Suppressive effect of glutamate receptor antagonist (CNQX) on nesfatin-
1 neuronal activation induced by glucose injection
The animals were divided into three groups (n=5 per group). After a 48-hour fasting
period, the control group received saline (400 µl saline, intraperitoneally [ip]), the glucose 
group was injected with glucose (2 g/kg glucose in 400 µl saline, ip) and the antagonist 
group was injected with non-NMDA glutamate antagonist (2 mg/kg CNQX in 400 µl 
saline, ip) 15 minutes before the glucose injection. The dosage of glucose injection was 
determined by referring the previous reports in the literature (21, 46-47).
Tissue preparation
All injections were performed between 9:00 and 11:00 am and 90 minutes after 
injection, the animals were deeply anesthetized with ether and fixed by trans-cardiac 
perfusion with 4% paraformaldehyde (PFA) in 0.13 M Sorenson’s phosphate buffer, pH 7.4
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(300 ml/animal). Brains and brainstems were carefully removed and post-fixed overnight 
in the same fixative at +4°C. Five series of brain sections with a thickness of 40 μm were 
taken along the rostral-caudal axis of the hypothalamus with a vibratome and collected into
Tris-HCl buffer (0.05 M, pH 7.6). The brain sections were washed 3 times with Tris-HCl 
buffer (0.05 M, pH 7.6) and then stored at -20°C in cryoprotectant until use.
Immunohistochemistry
Tris-HCl buffer was used for all washing steps. Primary and secondary antibodies 
were diluted in blocking buffer (10% normal horse serum, 0.2% Triton X-100, and 0.1% 
sodium azide in Tris-HCl buffer) for 2 h in order to prevent non-specific binding. 
Following 2-h incubation in blocking buffer, sections were transferred into rabbit anti-c-
Fos antibody solution at a dilution of 1/20 000 (Chemican, Billerica, MA, USA). The 
sections were incubated in donkey anti-rabbit IgG (1/300 dilution, Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA) for 2 h, processed with avidin-
biotin complex according to the manufacturer’s instructions (ABC Elite Standard Kit, 
Vector Laboratories, Burlingame, CA, USA) for 1 h and stained with diaminobenzidine 
(DAB) solution (25 mg DAB, 2 g nickel ammonium sulfate, 2,5 µl hydrogen peroxide in 
100 ml Tris-HCl buffer). After washing, the sections were secondarily blocked with 10% 
normal horse serum, and incubated in rabbit anti-nesfatin-1 antibody (1/20 000 dilution, H-
060-50, Phoenix Pharmaceuticals, Inc., USA) overnight at room temperature. This step 
was followed by secondary antibody incubation using biotin conjugated donkey anti-rabbit
IgG (1/400 dilution, Jackson ImmunoResearch Labs, West Grove, PA, USA) for 2 h. DAB 
(25 mg DAB, 2.5 µl hydrogen peroxide in 50 ml Tris-HCl buffer) was used for 
visualization of the immunochemical complex. ). Double-stained sections were then 
transferred into Tris-HCl buffer, washed, mounted on glass slides, dried and coverslipped 
with DPX. 
c-Fos antibody used in this study have been used in many reports in the literature as
well as in our previous studies (17, 42). Nesfatin-1 antibody specifity was shown in 
previous studies in the literature (6).
Cell counting
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Sections were analyzed and photographed with Olympus BX-50 photomicroscope 
attached to a CCD camera (Olympus DP71, CCD color camera, 1.5 million pixels, 
Olympus Corporation, Japan). Sections between the coordinates determined according to 
the rat brain atlas (bregma -0.48 mm and -1,44 mm SON) were used for double 
immunohistochemical labeling (39). Cross sections taken at 5 different levels at the same 
coordinate and at equal distance for each animal in the rostrocaudal plane were used for 
cell counting. All nesfatin-1-positive cells, with and without c-Fos-positive nuclei neurons 
in the SON were counted bilaterally and blindedly in every fourth section between the 
stereotaxic coordinates of bregma -0.48 mm- bregma -1.44 mm. Then the percentage of c-
Fos-positive nesfatin-1 neurons to all nesfatin neurons was calculated within each animal 
in dual indirect immunoperoxidase-labeled sections. 
Statistical analysis
The percentage of the c-Fos positivity in nesfatin-1 positive cells is expressed as 
mean ± standard deviation. The significance of differences between the groups was 
assessed with ANOVA test. The level of statistical significance was set at P < 0.05. 
Statistical data analysis was performed with IBM SPSS, 23.0.
RESULTS
The agonist and antagonist injections did not cause adverse reactions or mortality 
during the experiments.
Nesfatin-1 positivity was visualized by brown reaction product with chromogen in 
the cytoplasm and c-Fos positivity by blue/black reaction product in the nuclei (Fig. 1). 
After the 48-h fasting, refeeding and ip glucose injection significantly increased the 
number of c-Fos-expressing nesfatin-1 neurons, compared with the fasting and saline 
controls. These effects were also blocked by antagonist injection (CNQX). 
Refeeding induced c-Fos expression in nesfatin-1 neurons and CNQX reduced the 
number of active nesfatin-1 neurons
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After refeeding for 2 h following 48 h fasting, c-Fos-immunoreactive neurons were 
observed abundantly in the SON, PVN.
The 2-h refeeding after 48-h fasting caused a significant increase in the number of 
c-Fos-positive nesfatin-1 neurons compared with the fasting group. These effects were also
blocked by antagonist (CNQX). In the refeeding group, about 66% of nesfatin-1 neurons 
localized in the SON were c-Fos-positive, whereas this ratio was 1% in the fasting group 
(P=0.000). The ratio of the activated nesfatin-1 neurons was reduced to 25% after CNQX 
injection (P=0.009). The number of nesfatin-1 neurons expressing c-Fos immunoreactivity 
was significantly (66 times) greater under refeeding, compared with fasting conditions 
(Table 1, Fig. 2, and Fig. 4A).
Glucose induced c-Fos expression in nesfatin-1 neurons and CNQX reduced the 
number of active nesfatin-1 neurons
After glucose injection following 48 h fasting, c-Fos-immunoreactive neurons were
observed abundantly in the SON, PVN.
The glucose injection after 48-h fasting significantly increased the number of c-
Fos-positive nesfatin-1 neurons compared with the control group. These effects were also 
blocked by antagonist (CNQX). The glucose injection activated about 55% of c-Fos-
positive neurons (55%, significantly more than in the control group: 1%, P=0.01). The 
ratio of the activated nesfatin-1 clearly decreased after antagonist injection (CNQX) (6%, 
P=0.01).
The number of c-Fos-expressing nesfatin-1 neurons was significantly increased 
following glucose injections when compared with saline conditions. The number of 
glucose-activated nesfatin-1 neurons was significantly reduced if CNQX was pre-injected 
(Table 1, Fig. 3, and Fig. 4B).
DISCUSSION
Nesfatin-1 is a newly identified peptide that has regulatory effects on food and 
water intake, energy consumption, cardiovascular and gastrointestinal functions, anxiety 
and depression and reproductive functions (41). Although there is some literature on the 
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effects of nesfatin-1 neurons in the target cells and organs, no experimental studies have 
been found on central neurotransmitter systems. In the present study, we investigated the 
hypothesis that nesfatin-1 neurons are activated by refeeding and glucose injection as 
peripheral and metabolic factors and that the glutamatergic system has regulatory 
influences on nesfatin-1 neurons in the SON. 
The regulatory effects related to neurogenesis, apoptosis, neurite development and 
synapse formation of glutamate, the main excitatory neurotransmitter of the central 
nervous system, on the hypothalamic neuroendocrine systems, is intensively investigated 
(12-14, 32). Glutamate is the dominant excitatory transmitter in neuroendocrine regulation 
in the hypothalamus. There were large amounts of glutamate in boutons making synaptic 
contact with neuroendocrine neurons in the arcuate, paraventricular, and supraoptic nuclei. 
The immunohistochemical studies showed that high level glutamate-immunoreactive 
terminals were present in the SON. Glutamate is also one of the major excitatory 
neurotransmitters in the SON (31). In our laboratories we showed that kainic acid activates
oxytocinergic neurons through non-NMDA glutamate receptors in the SON and PVN (34). 
Our immunohistochemical studies showed that systemic administration of ionotropic non-
NMDA and NMDA glutamate receptor agonists directly or indirectly activate 
neuronostatin neurons at different rates (42). Also, we detected increased number of c-Fos 
positive nesfatin-1 neurons in kainic acid, AMPA and NMDA injected subjects in the SON 
(18). In addition, expression of the ionotropic glutamate receptors has been demonstrated 
with fluorescence microscopy on nesfatin-1 neurons in the SON (18). In the present study, 
after refeeding and glucose injection, c-Fos-immunoreactive neurons were observed 
abundantly in the SON. We anayzed the SON for the effects of the glutamatergic system on
nesfatin-1 neurons induced by refeeding and glucose injection.
The anorexigenic effect after injection into brain ventricles of nesfatin-1 has been 
studied in various animal groups such as rats (25, 44, 50),  mice (3, 16), pigs (26) and 
goldfish (19), and it has been found to have a strong anorexigenic effect. Inhibition of dark 
phase food intake after third ventricle injection of nesfatin-1 has been described (35). Low 
dose injection into the 4th ventricle of nesfatin-1 has been shown to reduce food intake in 
the first 4 hours and suppress cumulative food intake in the 5th hour (43). 
Intracerebroventricular (ICV) injection of nesfatin-1 has been shown to reduce water 
intake as well as food intake (48). In the SON, refeeding has been shown to activate the 
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number of nesfatin-1-immunoreactive neurons and mRNA expression of NUCB2 (23). 
Refeeding after fasting also increased the number of c-Fos-positive nesfatin-1 neurons in 
the SON (23). Our results not only confirmed this previous report by showing that 
activation of the nesfatin-1 neurons was caused by refeeding after fasting, but also that this 
activation was significantly suppressed by the administration of the AMPA/kainate 
receptor antagonist CNQX. This result suggests that the regulatory effect of glutamate on 
nesfatin-1 neurons is unique. In our previous study, we showed that 2-h refeeding after 48-
h fasting induced pSTAT5 expression in the neuronostatin neurons in the anterior 
hypothalamic periventricular nucleus and this expression was significantly suppressed by 
glutamate receptor antagonist (CNQX) (42). This information supports that a peripheral 
factor, such as refeeding, was effective in regulating the functions of nesfatin-1 neurons 
and that this effect was mediated through the glutamatergic system.
CNQX application to the fasting group was considered while designing the 
presented study. But in preliminary experiments, c-fos positivity was only 1% in nesfatin 
neurons in the fasting group. We did not use this group because we predicted that CNQX 
administration before fasting will not significantly change the activation of nesfatin 
neurons.
The hypothalamus plays an important role in regulating food intake and glucose 
homeostasis (33). Glucose is the primary fuel for the brain and enters the CNS with the 
high affinity glucose transporter (GLUT) type 1 (2). Glucosensitive and glucoresponsive 
neurons are found in the hypothalamic nuclei and participate in glucose homeostasis (33). 
Glucose sensitive neurons are glucose-activated or glucose-inhibited neurons. Glucose 
sensitive neurons are found in the hypothalamic nuclei such as ARC, PVN, SON, VMH, 
and lateral hypothalamus, and respond to blood glucose changes (33). Neuronal activation 
of the hypothalamic nuclei after glucose infusion has been demonstrated using the c-Fos as
the neuronal activation marker. The number of c-Fos-positive neurons peaks in 90 minutes 
after stimulus as a response to acute physiological stimuli. After intracarotid glucose 
injection, c-Fos, immunoreactive neurons are detected in PVN and VMH. The number of 
c-Fos-positive neurons in ARC and PVN was significantly higher than in the saline group 
(33). We not only found that glucose injection after fasting dramatically increased the 
number of c-Fos immunoreactive-nesfatin-1 neurons in the SON but also determined that 
the number of active nesfatin-1 neurons was significantly reduced after glutamate receptor 
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antagonist (CNQX) injections. This information suggests that nesfatin-1 neurons are 
glucose sensitive neurons and glutamatergic system regulates this mechanism.
In the present study, the increase in the number of activated nesfatin-1 neurons was 
observed to be about 66-fold with refeeding and 55-fold with glucose injection after 
fasting. These results suggest that refeeding and/or glucose injection after fasting led to 
activation of nesfatin-1 neurons and this activation was mediated by the intracellular 
pathway with c-Fos. This data also supports the possibility of an intracellular pathway 
using c-Fos as the trancription factor, has a role in the regulation of the physiological 
activities of nesfatin-1 neurons. Furthermore, the number of activated nesfatin-1 neurons 
was significantly suppressed by glutamate receptor antagonist (CNQX) application. To our 
knowledge, this is the first report that has shown the regulatory effect of glutamatergic 
system on nesfatin-1 neurons. Our previous studies supports that glutamate receptor 
antagonist (CNQX) can reach the central nervous system and affect the neuronal activation
(13, 18, 34, 42). Also, our data showed that nesfatin-1 neurons express glutamate receptor 
subunits (18). Taken together, we can suggest that glutamatergic signals may reach the 
nesfatin-1 neurons directly. Another possibility of course is that, an indirect mechanism 
involving glutamate-receptive interneurons may play a role in the regulation of 
nesfatinergic system.
It is important to implicate that the immunohistochemistry is limited to the 
detectable levels of the proteins that are analyzed in this study. Our results only include the
nesfatin-1 neurons that can be identified by immunohistochemistry, and the numbers 
provided in this study only represents these neurons.
CONCLUSIONS
In conclusion, this study demonstrated that refeeding and glucose intake highly 
selectively activates nesfatin-1 neurons in the SON. This activation suggests that nesfatin-1
neurons in the SON may play a role in the regulation of feeding behavior and glucose 
metabolism. The results also demonstrated that glutamate antagonist CNQX can 
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Table-I. The percentages of c-Fos-positive nesfatin-1 neurons relative to all nesfatin-1 
neurons in all groups (mean±standard deviation). P values pertain to the comparison with 
the refeeding and glucose-injected groups.
c-Fos expression (%)
Nesfatin-1 neurons P
Fasting 1.00±0.94 = 0.00
Refeeding 66.65±9.82
CNQX+Refeeding 25.15±17.22 < 0.009
Glucose Control 1.13±0.66 < 0.01
Glucose 55.7±21.46
CNQX+Glucose 6.32±9.60 < 0.01
*CNQX – cyano-7-nitroquinoxaline-2,3-dione
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Figure 1. Representative c-Fos-positive and c-Fos-negative nesfatin-1 neurons. The arrow-
head indicates c-Fos positivity (black) in the nucleus of a nesfatin-1-positive (brown) 
neuron. The arrow indicates a representative c-Fos-negative nesfatin-1 neuron.
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Figure 2. Effect of CNQX, a non-NMDA glutamate antagonist, in subjects stimulated by 
refeeding after fasting. Double-immunohistochemical staining of c-Fos and nesfatin-1 in 
SON after 48 h fasting (upper panel), after 2h refeeding following 48 h fasting (middle 
panel) and CNQX-treated subjects before feeding (lower panel).
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Figure 3. Effect of CNQX, a non-NMDA glutamate antagonist, in subjects stimulated by 
glucose injection. Double-immunohistochemical staining of c-Fos and nesfatin-1 in SON, 
after 48 h fasting; saline injection (upper panel), glucose injection (middle panel) and 
CNQX-treated subjects before glucose injection (lower panel).
Figure 4. The percentages of c-Fos-positive nesfatin-1 neurons relative to all nesfatin-1 
neurons. Effect of CNQX, a non-NMDA glutamate antagonist, in subjects stimulated by 
refeeding after fasting. There were significant differences between fasting-refeeding (***p 
< 0.001) groups and refeeding-antagonist groups (**p < 0.01) (A). Effect of CNQX, a non-
NMDA glutamate antagonist, in subjects stimulated by glucose injection. There were 
significant differences between glucose control-glucose and glucose-antagonist 
(CNQX+glucose) groups (*p <0.05) (B).
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